| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | ABIOMED INC | 1,450,000 | 158,471,000 | 39.93% | ||
| 2 | ENTELLUS MEDICAL INC | 3,813,197 | 69,667,000 | 17.55% | ||
| 3 | REVANCE THERAPEUTICS INC COM | 4,592,047 | 62,452,000 | 15.74% | ||
| 4 | AXOGEN INC | 4,861,111 | 33,444,000 | 8.43% | ||
| 5 | CORIUM INTERNATIONAL INC | 9,353,304 | 32,456,000 | 8.18% | ||
| 6 | ENDOLOGIX INC | 1,257,468 | 22,174,000 | 5.59% | ||
| 7 | MEDICINOVA INC COM NEW | 1,170,370 | 8,836,000 | 2.23% | ||
| 8 | LIGAND PHARMACEUTICALS INC | 32,893 | 3,923,000 | 0.99% | ||
| 9 | ACURA PHARMACEUTICALS INC | 1,956,397 | 3,619,000 | 0.91% | ||
| 10 | Catalyst Biosciences | 1,179,352 | 1,824,000 | 0.46% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001172661-16-003672, filed 2016.08.09).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
